Skip to content
Search

Latest Stories

Amazon launches online pharmacy in India

US tech giant Amazon launched its first Indian online pharmacy service on Friday (14) as it attempts to grab more of the country's burgeoning e-commerce market.

Amazon is battling Walmart-backed Flipkart and JioMart, owned by Asia's richest man Mukesh Ambani, as well as local companies in the vast market of 1.3 billion people.


India has seen nearly 2.5 million confirmed coronavirus infections -- more than any other country besides the United States and Brazil -- and healthcare startups are seeing huge demand for services as a result of the pandemic.

Customers in Bangalore, India's IT hub, will be able to order prescription and over-the-counter medicines and basic health devices from certified sellers, Amazon India said in a statement.

"This is particularly relevant in present times as it will help customers meet their essential needs while staying safe at home," Amazon said.

The firm owned by Jeff Bezos, the world's richest person, will also conduct pilot projects in other Indian cities, a company spokeswoman told AFP.

Amazon already offers online pharmacy sales in the US and several European countries, and has registered "Amazon Pharmacy" trademarks elsewhere, the spokeswoman added.

India's digital health market is forecast to explode from around $4.5 billion in the current financial year to $25 billion by 2025, according to consulting agency RedSeer.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less